Technical analysis of Achieve Life Sciences, Inc. (ACHV): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom.
Price Performance
| 1 month | -0.29% |
| 3 months | +54.60% |
| Year-to-date | +50.87% |
| 1 year | +153.31% |
| 3 years | +65.16% |
| 5 years | -9.44% |
52-Week Range
| 52-week High | $8.64 |
| 52-week Low | $2.62 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $7.07 |
| SMA 200 | $5.25 |
| Beta | 1.96 |
| 30-day Volatility (annualised) | 61.8% |
| Price vs SMA 50 | +6.1% |
| Price vs SMA 200 | +42.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.12 | |
| 2025-11 | $4.87 | -4.9% |
| 2025-12 | $4.97 | +2.1% |
| 2026-01 | $4.18 | -15.9% |
| 2026-02 | $4.56 | +9.1% |
| 2026-03 | $2.94 | -35.5% |
| 2026-04 | $4.39 | +49.3% |
| 2026-05 | $5.24 | +19.4% |
| 2026-06 | $6.53 | +24.6% |
| 2026-07 | $6.42 | -1.7% |
| 2026-08 | $7.94 | +23.7% |
| 2026-09 | $7.50 | -5.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $7.42 |
| Market Cap | $762M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -48.65 |
| EV / EBITDA | -7.43 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -1.02 |
| Current Ratio | 0.95 |